Q-omics provides the consensus-scored ARL5AP3 profile across patient tissues and cancer cell-line models. ARL5AP3 expression is associated with patient survival in 14 of 34 cancer types, with the highest sampling consensus in UCS. Among the 18 cancer types available for tumor–normal comparison, ARL5AP3 is differentially expressed in 8, with the highest sampling consensus in BRCA. Additionally, ARL5AP3 RNA expression shows 14,988 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight UCS, BRCA, and THYM as cancer lineages where ARL5AP3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ARL5AP3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ARL5AP3 survival associations across molecular data types. ARL5AP3 RNA expression shows survival associations in the most cancer types (14). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ARL5AP3 RNA expression–survival associations across cancer types. High ARL5AP3 expression shows unfavorable associations in COAD, UCEC, LGG, SKCM and LUAD, but favorable associations in UCS. The UCS Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify UCS as the clearest survival context for ARL5AP3 RNA expression.
This table summarizes ARL5AP3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for ARL5AP3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ARL5AP3 shows lower tumor expression in BRCA, BLCA, LUSC, LUAD, STAD and COAD. The BRCA box plot shows higher ARL5AP3 RNA expression in normal versus tumor tissue (log2 FC = −0.352, t-test p < 0.001).
This table shows molecular features associated with ARL5AP3 in patient tissues and cancer cell lines. In patient samples, ARL5AP3 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
